Positive high-level results from a prespecified interim analysis of the I CAN Phase III trial showed that Ultomiris (ravulizumab) met its primary ...

Researchers have found that slowing ageing may not be linked to dietary restriction as previously believed, but rather to regulating the activity of an immune protein known as Complement component 3 ...

As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential ...

The U.S. Navy is accelerating its push into directed energy weapons as drone threats ...

Vector-10 is a registered trademark and patented technology of Vera Clinic. All clinical data collected under institutional ...

Yale researchers have previously shown that people who undergo moderate calorie restriction—a 14% reduction in calorie intake ...

NAB believes that with GPS increasingly recognized as a potential single point of failure, BPS has an important role to play.

At 2,000 employees, it would be more than half the head count at its current headquarters in Seattle's Sodo neighborhood, ...

Certainly, cravings can get the best of us and in some cases too much of what we crave can result in some unhealthy outcomes.

Kyverna Therapeutics reported robust early Phase 2 miv-cel data in gMG, showing 100% response rates and deep, durable ...

Recurring revenue mix -- 99% of revenue was recurring, providing high predictability and revenue visibility. Customer ...

Ouster activity within the NYSE Composite highlights lidar technology development, executive share movements, and evolving ...